Compare
Pluri Inc. vs ImageneBio, Inc. vs Inhibrx Biosciences, Inc. vs Outlook Therapeutics, Inc.
| Latest fiscal year | Pluri Inc. PLUR | ImageneBio, Inc. IMA | Inhibrx Biosciences, Inc. INBX | Outlook Therapeutics, Inc. OTLK |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | $1.02M | $800.0K | $1.30M | $1.41M |
| Revenue growth (YoY) | -24.0% | -77.1% | +550.0% | n/a |
| Gross margin | 44.6% | n/a | n/a | 4.0% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$23.82M | -$45.35M | -$140.06M | -$62.42M |
| EPS (Diluted) | -$2.44 | -$9.64 | -$9.04 | -$1.79 |
| Operating cash flow | -$19.59M | -$47.84M | -$129.79M | -$51.83M |
| Free cash flow | -$20.22M | n/a | -$129.82M | n/a |
| Cash & equivalents | $3.53M | $94.53M | $124.22M | $8.08M |
| Total assets | $24.88M | $152.98M | $146.48M | $18.58M |
| Total liabilities | n/a | $19.84M | $138.49M | $50.77M |
| Shareholders' equity | -$23.04M | $133.14M | $7.99M | -$32.19M |
| Return on year-end equity | n/a | -34.1% | n/m | n/a |
| Shares outstanding | 10.82M | n/a | 14.58M | 53.89M |
Revenue, most recent five fiscal years
| Fiscal year | Pluri Inc. | ImageneBio, Inc. | Inhibrx Biosciences, Inc. | Outlook Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $1.02M Ended 2026-06-30 | $800.0K Ended 2025-12-31 | $1.30M Ended 2025-12-31 | $1.41M Ended 2025-09-30 |
| 1 year earlier | $1.34M Ended 2025-06-30 | $3.50M Ended 2024-12-31 | $200.0K Ended 2024-12-31 | n/a |
| 2 years earlier | $326.0K Ended 2024-06-30 | $9.16M Ended 2023-12-31 | $1.80M Ended 2023-12-31 | n/a |
| 3 years earlier | $287.0K Ended 2023-06-30 | $15.62M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $234.0K Ended 2022-06-30 | $30.98M Ended 2021-12-31 | n/a | n/a |